HC Wainwright & Co. Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $14
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Orchestra BioMed Holdings with a Buy rating and set a price target of $14.
August 22, 2024 | 11:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Orchestra BioMed Holdings with a Buy rating and a price target of $14, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $14 by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100